10-Q: Nutra Pharma Corp. Reports Q2 2026 Results Amidst Financial Challenges

Nutra Pharma Corp. filed its Q2 2026 Form 10-Q, revealing substantial net losses, increased operating expenses, and a precarious liquidity position, with significant debt defaults continuing.

Summary

• Nutra Pharma Corp. reported its financial results for the second quarter and first six months ended June 30, 2026.
• The company experienced significant net losses in both periods, with a net loss of $3,948,772 for the three months and $4,408,447 for the six months ended June 30, 2026.
• Net sales decreased significantly compared to the prior year, with unrelated customer sales down 59.23% for the quarter and 61.07% for the six months.
• Operating expenses increased due to higher professional and consulting fees.
• The company has a substantial accumulated deficit of $82,686,976 and a stockholders deficit of $21,208,753 as of June 30, 2026.
• Significant indebtedness is in default, and the company faces substantial doubt regarding its ability to continue as a going concern.
• The company estimates it will require approximately $1,200,000 to fund operations over the next twelve months.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to significant net losses, substantial debt, ongoing defaults, and a severe liquidity crisis, indicating a high risk of continued financial distress.

Positives

• Gross profit margin for the three-month period improved to 56.33% from 51.93% in the prior year, partly due to lower manufacturing costs.
• The company has brought its financial reporting current as of October 2025.
• Expanded online marketing efforts for Nyloxin and Pet Pain-Away, including placement on Chewy.com.
• The company is pursuing international drug registrations and distribution partners.

Negatives

• Net sales to unrelated customers decreased by 59.23% for the three months and 61.07% for the six months ended June 30, 2026.
• Net sales to related party Avini Health decreased by 37.63% for the three months and 39.99% for the six months.
• Operating expenses increased by 32.24% for the quarter and 13.55% for the six months due to higher professional and consulting fees.
• The company reported a net loss of $3,948,772 for the three months and $4,408,447 for the six months ended June 30, 2026.
• Accumulated deficit reached $82,686,976 as of June 30, 2026.
• Stockholders deficit was $21,208,753 as of June 30, 2026.
• Significant indebtedness is in default, with $5,545,758 of convertible notes payable in default as of June 30, 2026.
• The company does not have sufficient cash to sustain operations for the next 12 months and requires additional financing.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to recurring losses, accumulated deficit, working capital deficit, and significant indebtedness in default.
• The company requires additional financing to fund operations and reduce debt, with no assurance of its availability.
• Failure to secure adequate funding could prevent the company from implementing expansion plans and repaying obligations.
• The company's common stock is on the OTC Market Groups Expert Market, limiting its ability to raise capital.
• Intense competition in the biotechnology and pain relief markets.
• Potential for adverse impacts from the economic downturn and credit market crisis on financing and operations.
• Risk of litigation and increased costs associated with extensive legal/regulatory requirements in the healthcare industry.
• Failure to successfully develop and commercialize products from research and development activities.

Future Outlook

The company requires approximately $1,200,000 to fund operations over the next twelve months, including employee compensation, consulting fees, office expenses, insurance, and legal/accounting services. Future success is dependent on securing additional financing, increasing ownership equity, attaining profitable operations, and successful product development and commercialization. There is substantial doubt about the company's ability to continue as a going concern.

Management Comments

• The company has expanded its online efforts to include marketing and social media consultants to expand sales of Nyloxin and Pet Pain-Away.
• The company has brought its financial reporting current as of October 2025.
• The company believes its Nyloxin products offer an alternative to opioid and acetaminophen-based pain relievers with a well-defined safety profile.
• The company is pursuing international drug registrations and distribution partners.
• The company's ability to continue as a going concern is contingent upon securing additional financing, increasing ownership equity, and attaining profitable operations.

Industry Context

StockSavvy.ai notes that Nutra Pharma operates in the highly competitive pain relief and biotechnology sectors. The company's reliance on homeopathic remedies and cobra venom-based products positions it in a niche market, while its drug discovery pipeline targets serious neurological conditions. The significant financial challenges and ongoing defaults highlight the inherent risks in early-stage biotechnology and pharmaceutical development, especially for companies with limited funding.

Comparison to Industry Standards

• The company's net sales are significantly lower than established pharmaceutical companies, indicating a small market share.
• The substantial operating losses and accumulated deficit are common in early-stage biotechnology firms but are severe in this case, suggesting a higher risk profile than industry averages.
• The company's reliance on convertible debt and promissory notes for financing is a common strategy for distressed companies, but the high incidence of defaults and the need for further capital raise concerns compared to companies with more stable financing structures.
• The company's drug development pipeline, particularly for RPI78M with Orphan Status for pediatric Multiple Sclerosis, aligns with industry trends of targeting rare diseases for expedited development, but progress appears stalled due to funding.

Legal Proceedings

• CSA 8411, LLC v. Nutra Pharma Corp.: Lawsuit settled in May 2025 for $125,000, with final payments made in February 2026.
• Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus: Lawsuit alleging fraud and securities law violations. A final judgment in July 2024 ordered disgorgement of $520,940, prejudgment interest of $59,295, and a $100,000 civil penalty. A total legal settlement amount of $680,235 has been accrued.

Related Party Transactions

• Sales to Avini Health (controlled by former CEO) decreased, but the company benefits from rent-free facility use and shared space.
• Accounts receivable from Avini Health were $21,567 as of June 30, 2026.
• Accrued interest to a director (Mr. Deitsch) was $215,081 as of June 30, 2026, related to a defaulted loan.
• Due to related parties totaled $1,773,851 as of June 30, 2026, primarily owed to an entity controlled by the former CEO.

Stakeholder Impact

• Shareholders face significant dilution risk if equity capital is raised to meet funding needs.
• Creditors and noteholders are at risk due to the company's defaults on significant debt obligations.
• Employees and consultants may face uncertainty regarding continued employment and compensation due to the company's going concern issues.
• Suppliers may face delayed or non-payment due to the company's financial distress.

Next Steps

• Secure additional financing to fund operations and reduce debt.
• Continue marketing efforts for Nyloxin and Pet Pain-Away, including expanding online presence.
• Pursue international drug registrations and distribution partnerships.
• Re-engage in the process of regulatory approval for Nyloxin in Canada.
• Initiate Phase I/II trials for RPI78M in late 2026, contingent on financing.
• Continue negotiations for settlements of defaulted notes.

Key Dates

Recommendation

The company exhibits severe financial distress, characterized by significant net losses, escalating debt, multiple defaults, and a critical liquidity crisis. The lack of clear path to profitability and the substantial doubt regarding its ability to continue as a going concern present an unacceptably high risk for investors. The potential for significant dilution from future capital raises further exacerbates the negative outlook.

Keywords

Nutra Pharma, Form 10-Q, Quarterly Report, Biotechnology, Pain Relief, Cobroxim, Nyloxin, Convertible Notes